Breakeven Is Near for Veracyte, Inc. (NASDAQ:VCYT)
Breakeven Is Near for Veracyte, Inc. (NASDAQ:VCYT)
Veracyte, Inc. (NASDAQ:VCYT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The US$3.2b market-cap company's loss lessened since it announced a US$74m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$9.3m, as it approaches breakeven. As path to profitability is the topic on Veracyte's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company.
Veracyte, Inc.(纳斯达克:VCYT)可能正在接近其业务的重大成就,因此我们希望为这家公司提供一些见解。 Veracyte, Inc.作为一家诊断公司在美国和国际上运营。 这家市值32亿美元的公司的亏损减少,因其在财务年度中宣布了7400万美元的亏损,而最新的十二个月滚动亏损为930万美元,正接近盈亏平衡。 由于盈利能力的道路是Veracyte投资者关注的话题,我们决定评估市场情绪。 下面我们将提供行业分析师对该公司的预期的高级总结。
Veracyte is bordering on breakeven, according to the 11 American Biotechs analysts. They expect the company to post a final loss in 2023, before turning a profit of US$28m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 46%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
根据11位美国生物科技分析师的说法,Veracyte正在接近盈亏平衡。 他们预计该公司将在2023年出现最后一次亏损,然后在2024年实现2800万美元的利润。 因此,该公司预计将在大约12个月内或更短时间内实现盈亏平衡。 为了实现预测中在12个月内盈亏平衡的共识估计,该公司需要以什么速度增长? 我们使用最优线计算得出一个年平均增长率为46%,这表明分析师的信心很高。 如果业务以较慢的速度增长,盈利将会比预期的更晚。
Given this is a high-level overview, we won't go into details of Veracyte's upcoming projects, however, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
鉴于这是一个高级概述,我们不会详细介绍Veracyte即将推出的项目,然而,请记住,大致而言,生物科技公司根据产品开发阶段,现金流的周期是不规律的。 这意味着,随着公司开始获得早期投资的利益,未来的大幅增长率并不罕见。
Before we wrap up, there's one aspect worth mentioning. Veracyte currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
在我们结束之前,有一个值得提及的方面。 Veracyte目前在其资产负债表上没有债务,这在现金耗尽的生物科技公司中是相当不寻常的,通常这类公司相对于其股本有较高的债务。 这意味着该公司完全依靠其股本投资运营,没有债务负担。 这一点降低了投资于亏损公司的风险。
Next Steps:
下一步:
There are key fundamentals of Veracyte which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Veracyte, take a look at Veracyte's company page on Simply Wall St. We've also compiled a list of essential aspects you should further research:
本文未涵盖Veracyte的一些关键基本面,但我们必须再次强调,这仅仅是一个基本概述。要更全面地了解Veracyte,请查看Simply Wall St上Veracyte的公司页面。我们还编制了一份您应该进一步研究的基本方面列表:
- Valuation: What is Veracyte worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Veracyte is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Veracyte's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Veracyte今天值多少钱?未来的增长潜力是否已经融入价格?我们免费研究报告中的内在价值信息图表有助于可视化Veracyte当前是否被市场低估。
- 管理团队:经验丰富的管理团队能够增加我们对业务的信心——请查看Veracyte的董事会成员以及CEO的背景。
- 其他高表现股票:是否还有其他股票提供更好的前景和经过验证的业绩?在这里查看我们这些优秀股票的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。